Grifols Reports Strong H1 2025 Financial Performance

SEC Filing 6-K (0001104659-25-071915)

Grifols, S.A. announced its financial results for the first half of 2025, showcasing significant growth across key metrics. Revenues increased by 7% to EUR 3,677 million, driven by a strong performance in the Biopharma segment, which grew by 8.2%. Adjusted EBITDA rose by 12.7% to EUR 876 million, reflecting a 23.8% margin. Net profit surged to EUR 177 million, nearly four times the figure reported in H1 2024. Free cash flow before M&A improved by EUR 182 million year-on-year, and the leverage ratio decreased to 4.2x. The company also reinstated a dividend payment of EUR 0.15 per share, signaling its commitment to shareholder returns. Grifols remains on track to launch Fibrinogen in Europe in Q4 2025 and in the U.S. in H1 2026, following FDA approval. The company reaffirmed its 2025 guidance, with improved free cash flow pre-M&A guidance to EUR 375-425 million.